BioCryst Pharmaceuticals
BCRX
BCRX
241 hedge funds and large institutions have $1.08B invested in BioCryst Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 83 increasing their positions, 69 reducing their positions, and 38 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
1% more funds holding
Funds holding: 238 → 241 (+3)
3% less call options, than puts
Call options by funds: $8.76M | Put options by funds: $9.04M
2.83% less ownership
Funds ownership: 87.32% → 84.49% (-2.8%)
Holders
241
Holding in Top 10
6
Calls
$8.76M
Puts
$9.04M
Top Buyers
| 1 | +$23.7M | |
| 2 | +$19.4M | |
| 3 | +$18.5M | |
| 4 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$14.2M |
| 5 |
Nuveen Asset Management
Chicago,
Illinois
|
+$11.6M |
Top Sellers
| 1 | -$62.1M | |
| 2 | -$50.2M | |
| 3 | -$17.2M | |
| 4 |
Citigroup
New York
|
-$13.3M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$8.21M |